Attached files
| file | filename |
|---|---|
| 8-K - Eloxx Pharmaceuticals, Inc. | v200577_8k.htm |
|
Company
Contact:
|
Investor Relations
Contact:
|
|
Senesco Technologies,
Inc.
|
Lippert/Heilshorn &
Associates, Inc.
|
|
Leslie J. Browne,
Ph.D.,
|
Anne Marie
Fields
|
|
President &
CEO
|
(afields@lhai.com)
|
|
(732)
296-8400
|
(212)
838-3777
|
SENESCO
TECHNOLOGIES REGAINS NYSE AMEX LISTING COMPLIANCE
NEW BRUNSWICK, N.J. (November 2, 2010) – Senesco
Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced
that the Company has received a letter from the NYSE Amex LLC (the "Exchange")
informing Senesco that it has now resolved matters related to the Company's
exchange listing compliance.
The
letter stated that based upon a review of publicly available information, the
Company has resolved the continued listing deficiency with respect to Section
1003(a)(iii) of the NYSE Amex LLC Company Guide referenced in the Exchange’s
letter dated October 29, 2009. The Exchange also indicated that, as
is the case for all listed issuers, the Company's continued listing eligibility
will be assessed on an ongoing basis and that the Company is subject to the
provisions of Section 1009(f) of the NYSE Amex Company Guide, which may be
accessed at www.nyse.com/regulation.
About
Senesco Technologies, Inc.
Senesco
Technologies is leveraging proprietary technology that regulates programmed cell
death, or apoptosis. Accelerating apoptosis may have application in
treating cancer, while delaying apoptosis may have application in certain
inflammatory and ischemic diseases. The Company is preparing to initiate a
human clinical trial in multiple myeloma with its lead therapeutic candidate
SNS01-T. Senesco has already partnered with leading-edge companies
engaged in agricultural biotechnology, and is entitled to earn research and
development milestones and royalties if its gene-regulating platform
technology is incorporated into its partners’ products.
Certain
statements included in this press release are forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Actual results could differ materially from such statements
expressed or implied herein as a result of a variety of factors, including, but
not limited to: the ability of the Company to consummate additional financings;
the development of the Company’s gene technology; the approval of the Company’s
patent applications; the successful implementation of the Company’s research and
development programs and collaborations; the success of the Company's license
agreements; the acceptance by the market of the Company’s products; success of
the Company’s preliminary studies and preclinical research; competition and the
timing of projects and trends in future operating performance, the Company’s
ability to continue to comply with the continued listing standards of the
NYSE/AMEX, as well as other factors expressed from time to time in the Company’s
periodic filings with the Securities and Exchange Commission (the
"SEC"). As a result, this press release should be read in conjunction
with the Company’s periodic filings with the SEC. The forward-looking
statements contained herein are made only as of the date of this press release,
and the Company undertakes no obligation to publicly update such forward-looking
statements to reflect subsequent events or circumstances.
#
# #